Trial Profile
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Fosdagrocorat (Primary) ; Prednisone
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 29 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 29 Oct 2013 Primary endpoint 'Disease-activity-score' has been met.
- 24 Mar 2012 This trial is recruiting in Spain.